N-Butylcyclohexanemethanamine | 87033-86-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Butylcyclohexanemethanamine
• 英文别名: N-(cyclohexylmethyl)butan-1-amine
• CAS: 87033-86-1
• 化学式: C₁₁H₂₃N
• mdl: MFCD08758128
• 分子量: 169.31
• InChiKey: XQIBCZAGCIOMII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  丁腈 、 环己甲醇 、 蓝宝石粉 以47%的产率得到
  参考文献：
  名称：

  KOZLOV, N. S.;ZHAVRID, A. S.;GLADKIX, L. V.;KOZINTSEV, S. I.;TARASEVICH, +, VESTSI AN BSSR. CEP. XIM. N., 1983, N 3, 57-60

  摘要：

  DOI：

文献信息

• Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
  申请人：Nishizawa Rena

  公开号：US20060178399A1

  公开（公告）日：2006-08-10

  A compound represented by the following general formula (I), its salt, solvates thereof or prodrugs thereof: (wherein each symbol is as defined in the description.) The compounds represented by the general formula (I) are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchoplumonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

  以下是通式（I）所代表的化合物、其盐、溶剂化物或前药：（其中每个符号如描述中所定义）。通式（I）所代表的化合物在预防和/或治疗各种炎症性疾病（哮喘、肾炎、肾病、肝炎、关节炎、类风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎等）、免疫性疾病（自身免疫性疾病、器官移植排斥、免疫抑制、银屑病、多发性硬化症等）、人类免疫缺陷病毒感染（获得性免疫缺陷综合症等）、过敏性疾病（特应性皮炎、荨麻疹、过敏性支气管肺曲霉病、过敏性嗜酸性胃肠炎等）、缺血再灌注损伤、急性呼吸窘迫综合症、细菌感染伴随的休克、糖尿病、癌转移等方面具有用途。
• Condensed ring compound and use thereof
  申请人：Takeuchi Jun

  公开号：US20060194797A1

  公开（公告）日：2006-08-31

  The present invention relates to a compound of formula (I) (wherein all symbols have the same meanings as described hereinbefore). The compound antagonizes cysLT 2 and therefore, it is useful as an agent for the prevention and/or treatment of respiratory diseases such as bronchial asthma, bronchial asthma, chronic obstructive pulmonary disease, pneumonectasia, chronic bronchitis, pneumonia (e.g. interstitial pneumonitis etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), and the like, or as an expectorant or antitussives.

  本发明涉及一种化合物，其化学式为(I)（其中所有符号的含义如前所述）。该化合物对cysLT2具有拮抗作用，因此，它可作为预防和/或治疗呼吸系统疾病（如支气管哮喘、慢性阻塞性肺疾病、肺气肿、慢性支气管炎、肺炎（如间质性肺炎等）、严重急性呼吸综合征（SARS）、急性呼吸窘迫综合征（ARDS）、过敏性鼻炎、鼻窦炎（如急性鼻窦炎、慢性鼻窦炎等）等，或作为祛痰药或止咳药物使用。
• Indole Compound and Use Thereof
  申请人：Takeuchi Jun

  公开号：US20080188532A1

  公开（公告）日：2008-08-07

  The present invention relates to a compound represented by the formula (I), wherein all symbols are as defined in the description, a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and/or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

  本发明涉及一种化合物，其表示为公式（I），其中所有符号如描述中所定义，其盐，溶剂化物或前药，具有期望比目前在临床试验中使用的白三烯受体拮抗剂更有效的白三烯受体拮抗作用。因此，它可用作预防和/或治疗白三烯介导的疾病，例如呼吸系统疾病，如支气管哮喘，慢性阻塞性肺疾病，肺气肿，慢性支气管炎，肺炎（例如间质性肺炎等），严重急性呼吸综合征（SARS），急性呼吸窘迫综合征（ARDS），过敏性鼻炎，鼻窦炎（例如急性鼻窦炎，慢性鼻窦炎等），或作为祛痰剂或止咳剂。
• Nitrogenous Heterocylic Derivative and Medicine Containing the Same as an Active Ingredient
  申请人：Takaoka Yoshikazu

  公开号：US20080057074A1

  公开（公告）日：2008-03-06

  A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

  化合物由公式（I）所表示，其盐，其N-氧化物，其溶剂合物或其前药：（其中每个符号如描述中所定义）。 公式（I）所表示的化合物具有对CCR5的拮抗活性，因此它们在预防和/或治疗CCR5相关疾病方面非常有用，例如各种炎症性疾病（哮喘，肾炎，肾病，肝炎，关节炎，类风湿关节炎，鼻炎，结膜炎，溃疡性结肠炎等），免疫性疾病（自身免疫性疾病，器官移植排斥（固体器官移植排斥，治疗糖尿病的胰岛细胞移植排斥，移植物抗宿主病等），免疫抑制，牛皮癣，多发性硬化等），传染病（人类免疫缺陷病毒感染，获得性免疫缺陷综合征，RSV感染等），过敏性疾病（特应性皮炎，荨麻疹，过敏性支气管肺曲霉病，过敏性嗜酸性胃肠炎等），心血管疾病（动脉硬化，缺血再灌注损伤等），急性呼吸窘迫综合症，伴随细菌感染的休克，糖尿病，癌转移等。
• NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Ochiai Hiroshi

  公开号：US20090233908A1

  公开（公告）日：2009-09-17

  A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

  化合物的化学式为（I）：（其中符号的定义与说明书中相同），其盐，N-氧化物，溶剂化合物或前药，以及其药用。化合物（I）具有CXCR4拮抗活性。因此，它可用作预防和/或治疗CXCR4介导疾病的药物，例如炎症/免疫疾病（例如类风湿性关节炎，关节炎，视网膜病变，肺纤维化和移植器官的排斥反应），过敏性疾病，感染性疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），心理神经疾病，脑部疾病，心血管疾病，代谢性疾病，癌症（例如癌症，癌症转移）或再生治疗剂。